336 related articles for article (PubMed ID: 31500224)
1. Protein Kinase CK2-A Putative Target for the Therapy of Diabetes Mellitus?
Ampofo E; Nalbach L; Menger MD; Montenarh M; Götz C
Int J Mol Sci; 2019 Sep; 20(18):. PubMed ID: 31500224
[TBL] [Abstract][Full Text] [Related]
2. Modulation of the pancreatic islet-stress axis as a novel potential therapeutic target in diabetes mellitus.
Ludwig B; Barthel A; Reichel A; Block NL; Ludwig S; Schally AV; Bornstein SR
Vitam Horm; 2014; 95():195-222. PubMed ID: 24559919
[TBL] [Abstract][Full Text] [Related]
3. Protection of pancreatic beta-cells: is it feasible?
Bonora E
Nutr Metab Cardiovasc Dis; 2008 Jan; 18(1):74-83. PubMed ID: 18096375
[TBL] [Abstract][Full Text] [Related]
4. Insulin gene therapy for type 1 diabetes mellitus.
Handorf AM; Sollinger HW; Alam T
Exp Clin Transplant; 2015 Apr; 13 Suppl 1():37-45. PubMed ID: 25894126
[TBL] [Abstract][Full Text] [Related]
5. Clinical utility of insulin and insulin analogs.
Sanlioglu AD; Altunbas HA; Balci MK; Griffith TS; Sanlioglu S
Islets; 2013; 5(2):67-78. PubMed ID: 23584214
[TBL] [Abstract][Full Text] [Related]
6. MST1: a promising therapeutic target to restore functional beta cell mass in diabetes.
Ardestani A; Maedler K
Diabetologia; 2016 Sep; 59(9):1843-9. PubMed ID: 27053234
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of cholinergic potentiation of insulin secretion from pancreatic islets by chronic elevation of glucose and fatty acids: Protection by casein kinase 2 inhibitor.
Doliba NM; Liu Q; Li C; Chen P; Liu C; Naji A; Matschinsky FM
Mol Metab; 2017 Oct; 6(10):1240-1253. PubMed ID: 29031723
[TBL] [Abstract][Full Text] [Related]
8. Adult-onset autoimmune diabetes: current knowledge and implications for management.
Buzzetti R; Zampetti S; Maddaloni E
Nat Rev Endocrinol; 2017 Nov; 13(11):674-686. PubMed ID: 28885622
[TBL] [Abstract][Full Text] [Related]
9. Functional interplay between the transcription factors USF1 and PDX-1 and protein kinase CK2 in pancreatic β-cells.
Spohrer S; Groß R; Nalbach L; Schwind L; Stumpf H; Menger MD; Ampofo E; Montenarh M; Götz C
Sci Rep; 2017 Nov; 7(1):16367. PubMed ID: 29180680
[TBL] [Abstract][Full Text] [Related]
10. Targeting Protein Kinases to Protect Beta-Cell Function and Survival in Diabetes.
Dalle S
Int J Mol Sci; 2024 Jun; 25(12):. PubMed ID: 38928130
[TBL] [Abstract][Full Text] [Related]
11. Targeting the pancreatic β-cell to treat diabetes.
Vetere A; Choudhary A; Burns SM; Wagner BK
Nat Rev Drug Discov; 2014 Apr; 13(4):278-89. PubMed ID: 24525781
[TBL] [Abstract][Full Text] [Related]
12. GLP-1 Receptor Agonists and Type 1 Diabetes - Where Do We Stand?
Popovic DS; Stokic E; Popovic SL
Curr Pharm Des; 2015; 21(36):5292-8. PubMed ID: 26438316
[TBL] [Abstract][Full Text] [Related]
13. Insulin Action Research and the Future of Diabetes Treatment: The 2017 Banting Medal for Scientific Achievement Lecture.
Accili D
Diabetes; 2018 Sep; 67(9):1701-1709. PubMed ID: 30135131
[TBL] [Abstract][Full Text] [Related]
14. Islet α cells and glucagon--critical regulators of energy homeostasis.
Campbell JE; Drucker DJ
Nat Rev Endocrinol; 2015 Jun; 11(6):329-38. PubMed ID: 25850661
[TBL] [Abstract][Full Text] [Related]
15. Indonesia Cohort of IO HAT Study to Evaluate Diabetes Management, Control, and Complications in Retrospective and Prospective Periods Among Insulin-Treated Patients with Type 1 and Type 2 Diabetes.
Rudijanto A; Saraswati MR; Yunir E; Kumala P; Puteri HH; Mandang VV
Acta Med Indones; 2018 Jan; 50(1):26-37. PubMed ID: 29686173
[TBL] [Abstract][Full Text] [Related]
16. Novel approaches to drug discovery for the treatment of type 2 diabetes.
Xu X; Wang G; Zhou T; Chen L; Chen J; Shen X
Expert Opin Drug Discov; 2014 Sep; 9(9):1047-58. PubMed ID: 25054271
[TBL] [Abstract][Full Text] [Related]
17. Type 2 diabetes mellitus.
DeFronzo RA; Ferrannini E; Groop L; Henry RR; Herman WH; Holst JJ; Hu FB; Kahn CR; Raz I; Shulman GI; Simonson DC; Testa MA; Weiss R
Nat Rev Dis Primers; 2015 Jul; 1():15019. PubMed ID: 27189025
[TBL] [Abstract][Full Text] [Related]
18. Targeting dysfunctional beta-cell signaling for the potential treatment of type 1 diabetes mellitus.
Fenske RJ; Kimple ME
Exp Biol Med (Maywood); 2018 Mar; 243(6):586-591. PubMed ID: 29504478
[TBL] [Abstract][Full Text] [Related]
19. Similar weight-adjusted insulin secretion and insulin sensitivity in short-duration late autoimmune diabetes of adulthood (LADA) and type 2 diabetes: Action LADA 9 [corrected].
Juhl CB; Bradley U; Holst JJ; Leslie RD; Yderstraede KB; Hunter S;
Diabet Med; 2014 Aug; 31(8):941-5. PubMed ID: 24628669
[TBL] [Abstract][Full Text] [Related]
20. Small molecule activators of the insulin receptor: potential new therapeutic agents for the treatment of diabetes mellitus.
Laborde E; Manchem VP
Curr Med Chem; 2002 Dec; 9(24):2231-42. PubMed ID: 12470244
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
